Skip to main content
. 2023 Jun 7;55(3):346–354. doi: 10.3947/ic.2022.0077

Table 1. Maternal characteristics.

Variables n (%)
Age (year), mean (SD) 34 (± 4.7)
Period
Pre-delta (Sep 2020 – May 2021) 1 (1.7)
Delta dominant (June 2021 – Jan 2022) 13 (21.7)
Omicron dominant (Feb 2022 – Apr 2022) 46 (76.7)
Gestational age (weeks), mean (SD) 38+2 (± 2+0)
Period between first positive SARS-CoV-2 test and delivery (day), median (IQR) 1 (0 - 2.3)
Birth-related complications 1 (1.7)
Method of delivery
Cesarean section 40 (66.7)
Vaginal delivery 20 (33.3)
Vaccination
Yes 9 (15.0)
No 33 (55.0)
Unknown 18 (30.0)
Underlying disease
Any disease 9 (15.0)
DM 4 (13.3)
Solid cancer 2 (3.3)
Cardiovascular disease 2 (3.3)
HTN 1 (1.7)
Pneumonia
Total 7 (11.7)
Pre Omicron dominant period 3 (5.0)
Omicron dominant period 4 (6.7)
Lymphocyte count, mean (SD) 1,208 (± 553.5)
Lymphocytopenia (<1,000/mcL)
Yes 16 (26.7)
No 22 (36.7)
Unchecked 22 (36.7)
CRP (mg/dL), mean (SD) 0.94 (± 0.76)
Elevated CRP (>0.6 mg/dL)
Yes 30 (50.0)
No 27 (45.0)
Unchecked 3 (5.0)
Elevated LD (>250 IU/L)
Yes 16 (56.7)
No 34 (26.7)
Unchecked 10 (16.7)
Oxygen supply 2 (3.3)
ICU care 0 (0.0)
Symptom
Any symptom 37 (61.7)
Fever 18 (70.0)
Chill 6 (10.0)
Cough 21 (35.0)
Sputum 9 (15.0)
Sore throat 13 (21.7)
Dyspnea 3 (5.0)
Rhinorrhea 4 (6.7)
Myalgia 6 (10.0)
Headache 7 (11.7)
Nasal congestion 3 (5.0)
Hyposmia 1 (1.7)
Hypogeusia 1 (1.7)
Severity
Asymptomatic 23 (38.3)
Mild illness 25 (41.7)
Moderate illness 10 (26.1)
Severe illness 2 (5.2)
Critical illness 0 (0.0)
Treatment
Regdanvimab 10 (16.7)
Dexamethasone 1 (1.7)
Remdesivir 1 (1.7)
Mechanical ventilation 0 (0.0)
In hospital mortality 0 (0.0)

SD, standard deviation; SARS-CoV-2, severe acute respiratory syndrome corona virus 2;

IQR, Interquatile range; DM, diabetes mellitus; HTN, hypertension; CRP, C-Reactive Protein; LD, Lactate Dehydrogenase; ICU, intensive care unit.